Presentation is loading. Please wait.

Presentation is loading. Please wait.

CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune.

Published byNatalia Serrano Modified over 5 years ago

Similar presentations

Presentation on theme: "CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune."— Presentation transcript:

1 CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells.
CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. A, Representative contour plots on CD94 and NKG2A staining on CD3+ T cells from paired tumor, paratumor, and PBMC samples from 1 patient with cancer (proportion of CD94/NKG2A+ T cells in tumor = 17.9%; in paratumor = 1.27%; and in PBMC = 0.3%). B, Correlative analysis on NKG2A and CD94 expression by MFI on tumor-derived CD3+ T cells. N, number of patients = 22 (esophageal cancer, n = 7; gastric cancer, n = 8; and colorectal cancer, n = 7); correlative analysis of nonparametric Spearman test, r2 = ; P < C, The frequency of CD94/NKG2C+ T cells from paired tumor (TUMOR), paratumor (PARA), and PBMC samples. N, number of patients = 22 (esophageal cancer, n = 7; gastric cancer, n = 8; and colorectal cancer, n = 7). D, Correlative analysis between the frequency of CD94/NKG2A+ CD3+ TILs with the HLA-E expression by MFI on EpCAM-specific tumor cells (left) and the HLA-E expression by MFI on tumor-derived CD141+ cDC (right). N, number of patients = 10 (esophageal cancer, n = 3; gastric cancer, n = 4; and colorectal cancer, n = 3); correlative analysis of nonparametric Spearman test, r2 = , P < (left); r2 = , P < (right). E, The proportion of CD94/NKG2A+ populations of CD3+ T cells, CD8+ T cells, NKT cells, and NK cells from paired tumor, paratumor, and PBMC. N, number of patients = 22 (esophageal cancer, n = 7; gastric cancer, n = 8; and colorectal cancer, n = 7); one-way ANOVA with Tukey post hoc analysis. F, The proportion of CD94/NKG2A+ population of CD4+ T cells derived from paired tumor, paratumor, and PBMC. N, number of patients = 22 (esophageal cancer, n = 7; gastric cancer, n = 8; and colorectal cancer, n = 7). G, The proportion of CD94/NKG2A+ and CD94/NKG2A− populations of CD8+ TILs according to TNM stage of clinical prognosis. N, number of patients = 22; (esophageal carcinoma, n = 7; gastric carcinoma, n = 8; and colorectal carcinoma, n = 7); two-way ANOVA with Tukey post hoc analysis. H, The proportion of CD94/NKG2A+ CD8+ TILs (left), CD94/NKG2A− CD8+ TILs (middle), and total CD8+ TILs (right) according to maturation phenotype expression of CD27, CD45RA, and CCR7 in carcinoma. (N, number of patients = 22; esophageal carcinoma, n = 7; gastric carcinoma, n = 8; and colorectal carcinoma, n = 7); one-way ANOVA with Tukey post hoc analysis. Horizontal line, median; interval, 95% confidence; connecting lines, samples from the same patients; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant. Data represent with median ± SEM. Megat Abd Hamid et al. Cancer Immunol Res 2019;7: ©2019 by American Association for Cancer Research

Download ppt "CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune."

Similar presentations

Suppl Figure 1 NSCLC OvCa A B

Suppl Figure 1 NSCLC OvCa A B
A All patients Arm A Arm B Deaths/patients 21/30 7/10 14/20

A All patients Arm A Arm B Deaths/patients 21/30 7/10 14/20
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma by Marion Lambert, Monique.

Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma by Marion Lambert, Monique.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Volume 20, Issue 12, Pages (September 2017)

Volume 20, Issue 12, Pages (September 2017)
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.

Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.
Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.

Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Tregs and APC subsets in TDLNs of patients with cervical cancer.

Tregs and APC subsets in TDLNs of patients with cervical cancer.
PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,

PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,
Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
Donor and recipient BAL T cells are phenotypically and functionally memory T cells. Donor and recipient BAL T cells are phenotypically and functionally.

Donor and recipient BAL T cells are phenotypically and functionally memory T cells. Donor and recipient BAL T cells are phenotypically and functionally.
Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Similar presentations

Ads by Google